Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$28.68 USD
-0.29 (-1.00%)
Updated Jun 12, 2024 04:00 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Brokerage Reports
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 681 - 700 ( 721 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
August Symphony Health Data for EXPAREL; Reiterate OUTPERFORM and $23 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of September 16
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Solid Momentum Behind EXPAREL Launch While Nerve Block Indication Provides Long-Term Value, In Our View.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
September and Remaining 2012 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EMA Concerns Regarding DepoCyte Manufacturing Not Material, In Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
July Symphony Health Data for EXPAREL; Reiterate OUTPERFORM and $18 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q2 EXPAREL Sales Beat as Launch Off to Very Promising Start; Reiterate OUTPERFORM and $18 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
August and Remaining 2012 Catalysts for Emerging Pharmaceuticals.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
June Wolters Kluwer Data for EXPAREL. Reiterate OUTPERFORM and $18 Fair Value.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
May Wolters Kluwer Data for EXPAREL Suggests Solid Second Month of Sales
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
New Health Economics Data Provides Compelling Marketing Tool for Exparel, In Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Movie Rental and Exhibitor Biweekly Newsletter-May 21 - June 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
April Wolters Kluwer Data for EXPAREL; Reiterate OUTPERFORM and $15 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1 Financials: We Believe April EXPAREL Sales Suggest Solid Start to Launch. Reiterate OUTPERFORM and $15 FV.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
We Estimate Financing Extends Cash Runway Into Potential Profitability - Reiterate OUTPERFORM, FV Lowered to $15
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EXPAREL Now Commercially Available-We Believe Groundwork Laid for a Successful aunch-Reiterate
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of April 1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals -Q2 2012 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L